Bella Ungar (Rami Eliakim, B Ungar)

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 7

Top Topics

Ulcerative Colitis

Top Venues

Alimentary pharmacology & therapeutics

United European gastroenterology journal

This page only lists publications with an associated author ORCID identifier.

Publications

Bella Ungar, Bella Ungar
Does pan-enteric capsule endoscopy obviate magnetic resonance entero-colonography in suspected Crohn's disease? United European gastroenterology journal (2022)
Bella Ungar, Miri Yavzori, Ella Fudim, Orit Picard, Uri Kopylov, Rami Eliakim, Dror Shouval, Yishai Levin, Alon Savidor, Shani Ben-Moshe, Rita Manco, Stav Dan, Adi Egozi, Keren Bahar Halpern, Chen Mayer, Iris Barshack, Shomron Ben-Horin, Shalev Itzkovitz
Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD. Gut (2022)
Bella Ungar, Uri Kopylov
Editorial: is vedolizumab effective for perianal Crohn's disease? Alimentary pharmacology & therapeutics 51 (9) (2020)
Bella Ungar, Shomron Ben-Horin, Xavier Roblin
Letter: double-dose intensification-a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors reply. Alimentary pharmacology & therapeutics 49 (6) (2019)
Shomron Ben-Horin, Bella Ungar, Uri Kopylov, Adi Lahat, M Yavzori, E Fudim, O Picard, Y Peled, R Eliakim, E Del Tedesco, Stephane Paul, Xavier Roblin
Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor. Alimentary pharmacology & therapeutics 47 (8) (2018)
S Ben-Horin, Bella Ungar, X Roblin
Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. Alimentary pharmacology & therapeutics 45 (5) (2017)
Haggai Bar-Yoseph, N Levhar, L Selinger, U Manor, M Yavzori, O Picard, E Fudim, Uri Kopylov, R Eliakim, S Ben-Horin, Y Chowers, Bella Ungar
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Alimentary pharmacology & therapeutics 47 (2) (2017)